Citigroup analyst Neena Bitritto-Garg maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $17 to $19.
Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $19
Citigroup analyst Neena Bitritto-Garg maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $17 to $19.
Related Posts
British Fashion Brand Burberry’s Q1 Comps Jump 18%
Burberry Group Plc (OTC: BURBY) registered a
Cannabis Market Competition Heats Up In Florida: Cresco Expands Portfolio As Legalization Looms
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) is expanding its cannabis brand portfolio in the Sunshine State to include the FloraCal and Cresco brands.
Google Eyes Expanding Pixel Smartphone Assembly to India: Strategy Follows Apple’s Footsteps
Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google is pursuing suppliers in India to assemble its Pixel smartphones, borrowing a leaf from Apple Inc's (NASDAQ: